World's Best Scientists 2026 revealed!
Harriet M. Kluger

Harriet M. Kluger

D-Index & Metrics

Medicine

D-Index
87
Citations
35398
World Ranking
13471
National Ranking
6849

Harriet M. Kluger publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Harriet M. Kluger sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 669 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Harriet M. Kluger D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Harriet M. Kluger sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Harriet M. Kluger is affiliated with Yale University in the United States and has contributed extensively to medical research, particularly in oncology and immunology. Their work spans several key subfields including oncology, immunology, molecular biology, pulmonary and respiratory medicine, and genetics.

The main areas of study for this scientist include cancer immunotherapy and biomarkers, CAR-T cell therapy research, immunotherapy and immune responses, brain metastases and treatment, melanoma and MAPK pathways, renal cell carcinoma treatment, and cutaneous melanoma detection and management.

Harriet M. Kluger has co-authored research with several frequent collaborators, including:

  • Lucia B. Jilaveanu
  • Sarah A. Weiss
  • Kelly Olino
  • Mario Sznol
  • David A. Schoenfeld

The scientist has published in multiple venues, with notable recurring publications in:

  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Cancer Research
  • Clinical Cancer Research

Selected recent papers authored or co-authored by Harriet M. Kluger include:

  • "Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial" (2020) in The Lancet Oncology
  • "Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma" (2021) in Journal of Clinical Oncology
  • "Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce" (2020) in Journal for ImmunoTherapy of Cancer
  • "KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements" (2021) in Nature
  • "Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study" (2022) in Journal for ImmunoTherapy of Cancer

Harriet M. Kluger's research output demonstrates a significant focus on advancing immunotherapy approaches for cancer treatment, including evaluation of novel therapeutic agents and resistance mechanisms.

Best Publications

  • Nivolumab plus Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Harriet Kluger;Margaret K. Callahan;Michael A. Postow

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.

    Michael Krauthammer;Yong Lin Kong;Byung Hak Ha;Perry Evans

  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

    Paul T. Nghiem;Shailender Bhatia;Evan J. Lipson;Ragini R. Kudchadkar

  • Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

    Sarah B Goldberg;Scott N Gettinger;Amit Mahajan;Anne C Chiang

  • Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas.

    Keith S Hoek;David L Rimm;Kenneth R Williams;Hongyu Zhao

  • Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

    Angeliki M. Stamatouli;Zoe Quandt;Ana Luisa Perdigoto;Pamela L. Clark

  • Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

    Rituparna Das;Rakesh Verma;Mario Sznol;Chandra Sekhar Boddupalli

  • Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

    David F. McDermott;Charles G. Drake;Mario Sznol;Toni K. Choueiri

  • Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

    Sarah B Goldberg;Kurt A Schalper;Scott N Gettinger;Amit Mahajan

  • Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

    Michael Krauthammer;Yong Kong;Antonella Bacchiocchi;Perry Evans

  • High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer

    Elah Pick;Yuval Kluger;Jennifer M. Giltnane;Christopher Moeder

  • Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

    M. F. Sanmamed;J. L. Perez-Gracia;K. A. Schalper;J. P. Fusco

  • Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

    Madhav V. Dhodapkar;Mario Sznol;Biwei Zhao;Ding Wang

  • Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy.

    Jing Hughes;Nalini Vudattu;Mario Sznol;Scott Gettinger

  • Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

    Paul Nghiem;Shailender Bhatia;Evan J. Lipson;William H. Sharfman

  • Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival

    Jonathan P. S. Knisely;James B. Yu;Jaclyn Flanigan;Mario Sznol

  • Early B cell changes predict autoimmunity following combination immune checkpoint blockade

    Rituparna Das;Noffar Bar;Michelle Ferreira;Aaron M. Newman

  • Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

    Jill C Rubinstein;Mario Sznol;Anna C Pavlick;Stephan Ariyan

  • Expression profiling reveals novel pathways in the transformation of Melanocytes to Melanomas.

    K. Hoek;D. Rimm;K. Williams;H. Zhao

Frequent Co-Authors

Mario Sznol
Mario Sznol Yale University
David L. Rimm
David L. Rimm Yale University
Yuval Kluger
Yuval Kluger Yale University
Ruth Halaban
Ruth Halaban Yale University
John M. Kirkwood
John M. Kirkwood University of Pittsburgh
Scott N. Gettinger
Scott N. Gettinger Yale University
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University
Marcus Bosenberg
Marcus Bosenberg Yale University
Michael A. Postow
Michael A. Postow Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative degrees and career options in healthcare can open doors to rewarding paths beyond the traditional MD route. For those seeking affordable entry into nursing, there are several cheapest bsn programs available online, allowing flexibility and reduced costs for aspiring nurses.

If you have a non-nursing bachelor’s degree, consider direct entry msn programs. These accelerated courses provide an efficient pathway to advanced nursing roles—no prior nursing experience required.

For individuals looking for programs that are more accessible, there are many nursing programs with high acceptance rates. These options help more students launch healthcare careers by reducing some competitive barriers.

Additionally, those interested in administrative roles can benefit from reputable online courses in health information. Review the best online medical billing and coding schools to discover programs with strong accreditation and available financial aid.

Whichever path you choose, online options offer the flexibility, affordability, and accessibility to get started in the medical field.

Best Scientists Citing Harriet M. Kluger

Trending Scientists

Recently Published Articles